Idiopathic Pulmonary Fibrosis
❖ ~250,000 patients in US and EU/year
❖ 755,000 new cases/yr
❖ Median IPF survival 2-5 years
❖ US ARDS market size $2.9B annually
❖ IPF growing at ~3% per year, accelerated by COVID-19 pandemic, large unmet
❖ Market Opportunity
❖ Two FDA-Approved Therapies for IPF
❖ Nintedanib & Perfenidone - Slow FVC decline, Poor tolerability, 25% discontinuation
